The differences in gene alteration rates reported by different authors (Table 2 and Table 3) may be related to limited sample sizes, to the variety of assays, gene panels, and depth of sequencing, to differences in tumor burden, ongoing therapies, or timing of sample collection (for example, alterations in APC and AR genes have been reported more frequently in relapse samples [52,54]), and to the possibility of hematopoietic variants (clonal hematopoiesis of indeterminate potential—CHIP) being misclassified as tumor derived [28,31,85]. The gene discussed is AR; the disease is neoplasm.